« Back
Home /
Prinomastat

Prinomastat

Item no.	HY-12170-5mg
Manufacturer	MedChem Express
CASRN	192329-42-3
Amount	5 mg
Quantity options	10 mMx1 mL 10 mg 1 mg 5 mg
Category	Oncology Food Safety Allergenes Neuroscience Neural Lineage Markers Neuroinflammation Molecular Targets for Neuroscience Neural Development Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.27
Formula	C18H21N3O5S2
Citations	Sci Adv. 2023 Jan 20;9(3):eadd3867. J Neuropathol Exp Neurol. 2022 Jun 3;nlac041. [1]Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. Bioorg Med Chem. 2003 Dec 1;11(24):5461-84. [2]Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010 Jul 15;10(2):198-208. [3]Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70. [4]Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000 Jun;20(6):447-53.
Smiles	O=C([C@@H]1N(S(=O)(C2=CC=C(OC3=CC=NC=C3)C=C2)=O)CCSC1(C)C)NO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AG3340; KB-R9896
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; MMP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	423.51
Product Description	Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, MMP-13 and MMP-9 with Kis of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : 2.5 mg/mL (ultrasonic; adjust pH to 3 with HCl)
Manufacturer - Pathway	Apoptosis; Metabolic Enzyme/Protease
Isoform	MMP-1; MMP-13; MMP-2; MMP-3; MMP-9
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12170-5mg-safety-datasheet.pdf